The intestinal microbiome influences immune recovery and long-term outcomes after allogeneic hematopoietic stem cell transplantation (allo-SCT). While reduced bacterial diversity and depletion of immunomodulatory microbial metabolites during peri-engraftment have been linked to acute graft-versus-host disease (aGvHD) and mortality, it remains unclear whether microbiome recovery after engraftment and immune reconstitution is better reflected by bacterial diversity or by microbial metabolic output. We aimed to define microbiome recovery in the late post-transplant period and test whether a metabolite-based biomarker improves the prediction of clinical outcomes, including overall survival (OS) and chronic (c) GvHD.

In this two-center longitudinal observational study, serial stool samples were collected from pre-transplant baseline to day +100 after allo-SCT in a discovery cohort (n = 20, Technical University Munich University Hospital (TUM)) and an independent validation cohort (n = 100, University Hospital Regensburg (UKR)). Gut microbiome composition was assessed by 16S rRNA gene amplicon sequencing, with metagenomic profiling in selected patients, and stool metabolites were quantified using targeted mass spectrometry. Patients were classified as RECOVERY or NO RECOVERY based on changes in bacterial richness between baseline and the post-transplant period. To capture microbial metabolic output, the previously established Immune-Modulatory Metabolite Risk Index (IMM-RI), comprising butyric, propionic, and isovaleric acids, desaminotyrosine and indole-3-carboxaldehyde, was adapted to the late posttransplant period (IMM-RI post-TX).

Bacterial alpha diversity frequently improved by day +100; however, this did not consistently indicate restoration of baseline community structure and was not paralleled by recovery of stool metabolite profiles. Accordingly, RECOVERY status showed a limited association with survival or transplant-related mortality (TRM). In contrast, IMM-RI post-TX low-risk identified patients with preserved butyrate-associated biosynthetic capacity and was significantly associated with improved OS in both cohorts (UKR: HR 0.2052, 95% CI 0.07703 – 0.5466, p < 0.0001). In the validation cohort, IMM-RI post-TX low-risk was significantly associated with reduced relapse related mortality. Interestingly, stool butyric-, propionic and valeric acid concentrations were increased in cGvHD of the skin, indicating context-dependent metabolite effects.

These findings suggest that metabolite profiling outperforms bacterial diversity for predicting outcomes after allo-SCT and support microbial metabolites as promising biomarkers for risk stratification and actionable candidates for precision microbiome interventions after allo-SCT.

Key points

- Metabolomic profiling outperforms microbial taxonomy for predicting long-term clinical outcomes in allo-SCT recipients

- Immune-Modulatory Metabolite Risk Index post-transplant is significantly associated with overall survival, relapse rate and incidence of chronic GvHD

Alix Schwarz: Honoraria: BeOne, AstraZeneca; travel: BeOne, AstraZeneca. Alexander Denk: honoraria: Medac; travel: Fabre, Neovii and Sanofi. Klaus Neuhaus: honoraria Hipp Matthias Fante: honoraria: Sanofi, Novartis; travel: Sanofi Andreas Hiergeist: honoraria: Roche Wolfgang Herr: honoraria: Amgen, Novartis; travel: Janssen-Cilag, Amgen. Simon Heidegger: employee of and holds equity interest in Roche/ Genentech. Florian Bassermann: honoraria: BMS, J&J, Amgen, Roche; travel: J&J. Daniel Wolff: research support: Novartis; honoraria: Sano, Incyte, Behring, Mallickrodt, Neovii and Takeda. Hendrik Poeck: honoraria: Novartis, Gilead, Abbvie, BMS, Pfizer, Servier, Janssen-Cilag; travel: Gilead, Janssen-Cilag, Novartis, Abbvie, Jazz, Amgen; Research: BMS. Erik Thiele Orberg: honoraria: AstraZeneca, BeOne, Takeda: travel: J&J, Lilly, Merck. All remaining authors declare no competing interest.

This study was supported by the Faculty Clinician Scientist Program of the Faculty of Medicine of TUM (fellowship to A.S.), the Deutsche Forschungsgemeinschaft, Projektnummer 395357507 SFB 1371 (to H.P., E.T.O., E.H., E.M., K.N., K.P.J., K.K., M.S.), Projektnummer 324392634 TRR 221 (to H.P., E.H., M.E., D.W., D.W., W.H., A.G.), Projektnummer 514894665 in TRR 387/1 (to F.B.), DFG PO 1575/5-1 (to H.P.), the German Cancer Aid (70114547 to H.P.), the Wilhelm Sander Foundation (2021.040.1 to H.P.), BA 2851/6 1 and BA 2851/7 1 to F.B., DFG under Germanys Excellence Strategy, the Else Kroener Fresenius Stiftung (funding line: Else-Kroener Forschungskolleg to E.T.O. and E.M.), the Deutsches Konsortium fuer Translationale Krebsforschung (fellowship to E.T.O. and A.S.), E.T.O. is supported by the DGIM Advanced Clinician Scientist Program. H.P. is supported by the EMBO Young Investigator Program and the Bavarian Cancer Research Center (BZKF) (to H.P., F.B., W.H.). This work was funded/co funded by the European Union (project MICROBOTS, Grant No. 101124680 to H.P.). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from all participants in accordance with study protocols approved by the institutional review boards of Technical university (295/18 S) and University clinic regensburg (14-47_1-101, 14-101-0047, 21-2521-01).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes